Will intensive medical treatment reduce my major adverse cardiovascular events?
Intensive medical treatment (IMT) refers to a combination of high-dose statins, ACE inhibitors or ARBs, and aspirin. For women with angina and no obstructive coronary artery disease (ANOCA/INOCA), a large randomized trial found that IMT did not lower the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke over 2.5 years compared to usual care 2. However, other studies suggest that targeted treatment based on the specific cause of angina can improve symptoms and may reduce events in certain subgroups 13.
What the research says
A 2024 randomized trial involving 2,476 women with suspected ANOCA/INOCA compared intensive medical treatment (high-intensity statin, ACE inhibitor or ARB, and aspirin) to usual care. Over 2.5 years, there was no significant difference in the primary outcome of MACE (all-cause death, myocardial infarction, stroke, hospitalization for angina or heart failure) between the IMT group and the usual care group (HR=1.13, p=0.20) 2. Hospitalizations for angina were the most common event 2.
In contrast, the PROMISE trial focused on patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) and found that a stratified treatment approach—using comprehensive diagnostic testing to identify the underlying cause—significantly improved angina status at 12 months compared to standard care 3. The trial was stopped early due to clear benefits in the intervention group, and while the secondary endpoint of MACE did not reach statistical significance, the results suggest that targeted therapy may be more effective than a one-size-fits-all intensive regimen 3.
Another study using stress perfusion cardiac MRI (CMR) to guide treatment in ANOCA patients found that CMR-guided management led to higher treatment satisfaction and more appropriate medication prescribing at 12 months compared to angiography-guided care 1. This highlights the importance of identifying the specific mechanism of angina (e.g., microvascular dysfunction) to tailor therapy 1.
For patients with acute coronary syndromes, intensive statin therapy (atorvastatin 80 mg) reduced the risk of MACE by 16% compared to moderate statin therapy (pravastatin 40 mg) over 2 years 4. However, this study included patients with obstructive coronary artery disease, not ANOCA/INOCA, so the results may not apply directly 4.
What to ask your doctor
- What is the specific cause of my angina? Could I have microvascular dysfunction or another non-obstructive cause?
- Would a stress perfusion cardiac MRI or other advanced testing help guide my treatment?
- Given that intensive medical treatment did not reduce MACE in the ANOCA/INOCA trial, what are the potential benefits and risks of taking high-dose statins, ACE inhibitors, and aspirin for me?
- Are there lifestyle interventions, such as a telemedicine-supported program, that could help improve my symptoms and reduce my risk?
- Should I consider a stratified treatment approach based on my individual test results rather than a standard intensive regimen?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.